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ABSTRACT
Background: Patients with type 2 diabetes mellitus (T2DM) are frequently diagnosed with some abnormal 
liver features. These liver abnormalities are suggested to be correlated with insulin resistance. The aim of this 
study was to evaluate liver abnormalities and fasting insulin levels in patients with T2DM.
Method: This study was conducted in Koja Hospital from February to July 2013. Study design was analytical 
study. Data for sex, age, complication, body mass index (BMI), liver function, liver enzyme, and fasting insulin 
level were collected. Univariate and bivariate statistical analyses were done using SPSS 20. 
Results: Twenty eight patients were included in this study, 71.43% of them were female. The age group of 
40-60 years was the highest among the patients (64.28%). Highest complication was neuropathy, BMI of most 
patients were obese. Liver abnormalities were documented in 35.8% patients, liver enzyme increased in 21.4% 
patients. Non alcoholic fatty liver disease (NAFLD) were noted in 46.6% patients, and one patient was positive 
for hepatitis B. Mean fasting insulin in T2DM with NAFLD were higher than in T2DM without NAFLD. However, 
it was not statistically significant (40.08 ± 36.8 μU/mL vs. 54.3 ± 37.1 μU/mL; p = 0.27).
Conclusion: Liver abnormalities found in T2DM patients were elevated liver enzyme, decreased albumin 
and increased of bilirubin. Through ultrasound, NAFLD and liver cirrhosis were found. Fasting insulin level 
was higher in T2DM with NAFLD but it was not statistically significant.
Keywords: type 2 diabetes mellitus, non alcoholic steato-hepatitis, fasting insulin
ABSTRAK
Latar belakang: Pada diabetes melitus tipe 2 (DMT2) sering ditemukan adanya gangguan hati. Gangguan 
hati ini diduga berhubungan dengan resistensi insulin. Tujuan penelitian ini adalah untuk mengevaluasi gangguan 
hati dan kadar insulin puasa pada DMT2.
Metode: Penelitian dilakukan di Rumah Sakit Koja dalam periode Februari – Juli 2013. Desain penelitian 
adalah studi analitik. Didata jenis kelamin, usia, komplikasi kronik, indeks massa tubuh (IMT), fungsi hati, enzim 
hati, dan kadar insulin puasa. Analisis data univariat dan bivariat dilakukan dengan menggunakan SPSS 20.
Hasil: Didapatkan 28 pasien sebagai subjek penelitian, terbanyak perempuan (71,43%), dan usia 40 - 60 tahun 
(64,28%). Sebagian besar pasien tergolong obesitas dan komplikasi kronik terbanyak adalah neuropatiperifer. 
Kelainan fungsi hati ditemukan pada 35,8% pasien, peninggian enzim hati pada 21,4% pasien. Gambaran hasil 
ultrasonografi (USG) penyakit perlemakan hati non alkoholik (PPHNA) didapatkan pada 46,4%, dan virus 
hepatitis B positif pada satu pasien. Rerata insulin puasa pada DMT2 dengan PPHNA lebih tinggi dari DMT2 
tanpa PPHNA namun tidak bermakna secara statistik (40,08 ± 36,8 μU/mL vs. 54,3 ± 37,1 μU/mL; p = 0,27).
Simpulan: Gangguan hati pada DMT2 adalah peningkatan enzim hati, penurunan kadar albumin serta 
peningkatan bilirubin. Pada USG didapatkan PPHNA dan sirosis hati. Kadar insulin puasa lebih tinggi pada 
DMT2 dengan PPHNA, walaupun tidak bermakna secara statistik.
Kata kunci: diabetes melitus tipe 2, penyakit perlemakan hati non alkoholik, insulin puasa
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INTRODUCTION
American Diabetes Association (ADA) 2005 and 
World Health Organization (WHO) define diabetes 
mellitus (DM) as a group of metabolic diseases.1,2,3,4 
Several liver abnormalities are often observed in 
diabetic patients, e.g. liver enzymes elevation in 
alanin transaminase (ALT) and aspartate transaminase 
(AST), non-alcoholic fatty liver disease (NAFLD), 
liver cirrhosis, hepatitis B and hepatitis C.5 This fact 
suggests the importance of liver enzymes evaluation 
before patients were prescribed with oral hypoglycemic 
agent.6
Approximately 50% patients with NAFLD were 
documented to have insulin resistance (IR). The strong 
correlation between metabolic syndromes with NAFLD 
is already highlighted.7 In the study by Compean et al 
comparing hepatogenous diabetes (HD) and T2DM, 
the 2 hours postprandial glucose/fasting glucose 
ratio, fasting insulin level and homeostasis model 
assessment (HOMA) IR were higher in HD group. 
Population with hepatitis B or hepatitis C has higher 
prevalence for diabetes.8 Another study performed in 
Greece revealed that 14% of patients with hepatitis B 
and 13% of patients with hepatitis C were diabetic. The 
co-existance between diabetes and chronic hepatitis are 
corellated with liver fibrosis severity.9
Insulin resistance is determined with various 
methods. The best method is the hyprinsulinemic-
euglycemic clamp technique. However the technique 
is very complicated because it requires invasive 
procedure, time wasting and expensive. Another 
method is the indirect method by measuring fasting 
insulin level and HOMA IR.10 Indirect fasting insulin 
level determination is widely used in clinical or 
epidemiological study. The aim of this study was to 
evaluate liver abnormalities and fasting insulin levels 
in patients with T2DM.
METHOD
All patients diagnosed with T2DM who visited 
Koja Hospital from February 1st – July 30th, 2013 
were included in this study. Sampling method was 
consecutive sampling. Subjects were excluded if 
they were documented to use a hepatotoxic and/
or hepatoprotector agent. Data for sex, age, chronic 
complication, body mass index (BMI); liver function 
(albumin, bilirubin and prothrombin time), liver 
enzyme (ALT and AST), hepatitis B and C virus, 
fasting insulin level, ultrasound of the liver were 
examined in order to capture fatty liver such as NAFLD 
or liver cirrhosis. Insulin resistance was determined by 
fasting insulin level. Initially all subjects with T2DM 
were collected for baseline characteristics. 
Further we take the largest proportion among liver 
abnormalities, and performed sub-analysis in those 
subgroups. We compare those groups with control 
group. Control group consist of T2DM, same sample 
size, sex, and age, without liver abnormalities. Mean 
difference in both groups were determined using 
independent T-test. All statistical analysis was done 
using computer software SPSS 20.
RESULT 
Total of 28 patients with T2DM were included. 
Most of the subjects were female, 40-60 years old age 
group, common chronic complication observed was 
peripheral neuropathy, length of DM < 5 years, and 
overweight/obese. Ten (35.8%) patients were noted 
to have abnormal liver function. Ten patients have a 
low plasma albumin and one patient also have elevated 
plasma bilirubin. Prothrombin time was within normal 
limit. Liver enzymes were elevated among 21.4% of 
patients. ALT was elevated in 6 patients, from which 
3 of them also have elevated AST. Fatty liver or on-
alcoholic steatohepatitis (NASH) was noted in 46.6% 
patients, and 1 patient HBsAg positive (Table 1).
We found liver abnormalities; 35.8% had abnormal 
liver function, 21.4% had elevated liver enzyme, 46.4% 
had fatty liver. Because fatty liver had the largest 
proportion among liver abnormalities (46.4%), we 
performed sub-analysis in this subgroup, by comparing 
fatty liver group with T2DM without fatty liver. 
Sub analysis was done in 13 patients with T2DM 
and NAFLD. Among this group, mean age was 55.3 ± 
9.8 years old, length of diabetes was 7.5 ± 5.2 years, 
BMI was 25.8 ± 3.9 kg/m2, and mean fasting insulin 
level was 56.8 ± 37.5 μU/mL. Another sub analysis in 
2 patients with liver cirrhosis revealed that the mean 
age was 55.5 ± 2.1 years old, length of DM 6.5 ± 2.1 
years, BMI 24 ± 4.2 kg/m2, and mean fasting insulin 
level 39.5 ± 23.2 μU/mL.
We did a sub analysis comparing 13 patients with 
NAFLD and 13 patients without NAFLD but the results 
were not statistically significant: mean age 55.3 ± 7.8 
years vs. 55.3 ± 9.8 years; p = 1, length of DM 4.8 ± 
4.5 years vs. 7.5 ± 5.2 years (p = 0.18), BMI 23.9 ± 
4.5 kg/m2 vs. 25.8 ± 3.9 kg/m2; p = 0.28, and fasting 
insulin level 40.08 ± 36.8 μU/mL vs. 54.3 ± 37.1 μU/
mL; p = 0.27 (Figure 1, 2, 3).
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Figure 1. Length of diabetes mellitus in 
T2DM group with and without non-
alcoholic fatty liver disease 
Figure 2. Body mass index in T2DM 
group with and without non-alcoholic 
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DISCUSSION 
 Most of patients in our study were female (71.4%). This finding was in contrast 
with study by Wild et al, in which patients were distributed equally.11 This happened 
because of the small sample size. 
Most of patients were 40-60 years old (67.9%). This finding was consistent with 
study by Wild et al.11 In his study most diabetic patients in developing country were 
around 45-64 years old, while in developed country most patients were ≥ 65 years old. 
Subgroup analysis were done in age subjects with NAFLD or without NAFLD, however 
the results were not statistically significant (55.3 ± 7.8 years old vs. 55.3 ± 9.8 years old, 
p = 1). 
Diabetes mellitus are recognized as risk factor for NAFLD.12 In our study, length 
of diabetes in T2DM with NAFLD was longer compared to T2DM without NAFLD, which 
are 4.8 ± 4.5 years vs. 7.5 ± 5.2 years. The difference was quite vary and confer the 
role of diabetes to develop NAFLD, however it was statistically significant (p = 0.18). 
BMI in 32.1% of patients were overweight, and 35.7% were obese. This number was 
lower compared to study by Kamath et al13 who found 48.9% subjects were obese. BMI 
are usually correlated with insulin resistance and NAFLD.12 In the subgroup analysis 
Figure 3. Fasting insulin (μU/mL) in T2DM group with or without non-alcoholic 
fatty liver disease 
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Most of patients were 40-60 years old (67.9%). This 
finding was consistent with study by Wild et al.11 In 
his study most diabetic patients in developing country 
were around 45-64 years old, while in developed 
country most patients were ≥ 65 years old. Subgroup 
analysis were done in age subjects with NAFLD 
or without NAFLD, however the results were not 
statistically significant (55.3 ± 7.8 years old vs. 55.3 
± 9.8 years old; p = 1).
Diabetes mellitus are recognized as risk factor for 
NAFLD.12 In our study, length of diabetes in T2DM 
with NAFLD was longer compared to T2DM without 
NAFLD, which are 4.8 ± 4.5 years vs. 7.5 ± 5.2 years. 
The difference was quite vary and confer the role of 
diabetes to develop NAFLD, however it was statistically 
significant (p = 0.18). BMI in 32.1% of patients were 
overweight, and 35.7% were obese. This number was 
lower compared to study by Kamath et al who found 
48.9% subjects were obese.13 BMI are usually correlated 
with insulin resistance and NAFLD.12 In the subgroup 
analysis (T2DM with NAFLD and without NAFLD), 
mean BMI was higher in group with NAFLD. However, 
it was not statistically significant (23.9 ± 4.5 kg/m2 vs. 
25.8 ± 3.9 kg/m2; p 0.28). All finding above could be 
explained due to the small sample size. 
Liver enzymes (ALT and/or AST) were elevated 
among 6 (21.4%) subjects. Among all patients 10 
(35.8%) subjects have low serum albumin level 
(and elevated serum bilirubin). These findings were 
consistent with study by Tolman et al and Gonem et 
al.5,14  They also documented the abnormal liver function 
and elevated liver enzyme in diabetic patients. They 
correlated the elevated liver enzymes and abnormal 
liver function with NAFLD. This phenomenon was 
associated with insulin resistance. Ultrasound results 
in our subjects recognized as NAFLD in 13 subjects 
(46.4%), and liver cirrhosis in 2 subjects. This findings 
consistent with previous study which approximately 
(37-74%) of diabetic patients have NAFLD.5
Fasting insulin off all patients were higher than 
normal; mean fasting insulin level 47.5 ± 36.3 μU/
mL vs. 12-15 μU/mL in normal population.15 In 
subgroup analysis, T2DM with NAFLD or T2DM 
without NAFLD, fasting insulin level were higher 
in the NAFLD group (40.08 ± 36.8 μU/mL vs. 54.3 
± 37.1 μU/mL; p = 0.27. These findings supports the 
evidence of insulin resistance in T2DM, especially 
in population with NAFLD, however it was not 
statistically significant. The underlying reason was due 
to unequal sample distribution. However, this issue 
could not be solved because of the small sample size.
Figure 1. Length of diabetes mellitus in T2DM group with and 
without non-alcoholic fatty liver disease
Figure 2. Body mass index in T2DM group with and without 
non-alcoholic fatty liver disease
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Figure 3. Fasting insulin in T2DM group with or without non-
alcoholic fatty liver disease
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CONCLUSION
Liver abnormalities found in T2DM were elevated 
liver enzyme, decreased albumin and increased of 
bilirubin, NAFLD and liver cirrhosis in ultrasound. 
Fasting insulin level was higher in T2DM with NAFLD 
but it was not statistically significant.
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